BACKGROUND: We previously reported 57% 12-month event free survival (EFS) in Malawian children with stage I to III Burkitt lymphoma (BL) with an intermediate dose chemotherapy protocol lasting 77 days. This protocol was shortened to 42 days and evaluated in children with stage I to IV disease for EFS and toxicity. METHODS: All Malawian children admitted to Queen Elizabeth Central Hospital, from 03/08/2000 to 12/03/2002 with confirmed BL were eligible. A fine needle aspirate, bone marrow aspirate, cerebrospinal fluid cytology, haemoglobin (Hb), white cell count (WCC), malaria smear, ELISA for HIV, and abdominal ultrasound were performed routinely. Murphy staging was used. The first dose of chemotherapy (COP1) consisted of 300 mg cyclophosphamide (CPM), 1 mg vincristine, and 60 mg prednisone given on day 1 and followed by COP2 on day 8 (only for patients with larger tumour volumes, stage III or IV disease). The vincristine dose in COP2 was 2 mg. COMP1 and 2 given on days 22 and 36 consisted of 500 mg CPM, 2 mg vincristine, 60 mg prednisone, and 2 g methotrexate. All doses were calculated per body surface area. Intrathecal methotrexate and hydrocortisone were given with COP1 and 2. RESULTS: Forty-two patients, 30 boys and 12 girls median ages 6 and 7.5 years, respectively, had Murphy stage I(n5), II(n8), III(n21), and IV(n8) disease. The face was involved in 74%, abdomen in 55%, bone marrow in 14%, kidneys in 24%, and 12% had paraplegia. Fourteen children died during or shortly after completion of chemotherapy. Three of these were disease related. Twelve patients suffered a local relapse after 57-328 days, and one a CNS relapse at 76 days. The projected EFS at 12 months is 50% in stage I, 50% in stage II, 24% in stage III, 25% in stage IV, and 33% for all patients. The cumulative mean dose of CPM was 62 mg/kg in survivors and 64 mg/kg in children who relapsed. One third of patients experienced significant marrow suppression, and infections after COMP1. CONCLUSIONS: Thirty-three percent of children are in first remission at 12 months. The morbidity and mortality of treatment was high. The high relapse rate in all stages may be due to the low cumulative dose of CPM. (c) 2004 Wiley-Liss, Inc.
BACKGROUND: We previously reported 57% 12-month event free survival (EFS) in Malawian children with stage I to III Burkitt lymphoma (BL) with an intermediate dose chemotherapy protocol lasting 77 days. This protocol was shortened to 42 days and evaluated in children with stage I to IV disease for EFS and toxicity. METHODS: All Malawian children admitted to Queen Elizabeth Central Hospital, from 03/08/2000 to 12/03/2002 with confirmed BL were eligible. A fine needle aspirate, bone marrow aspirate, cerebrospinal fluid cytology, haemoglobin (Hb), white cell count (WCC), malaria smear, ELISA for HIV, and abdominal ultrasound were performed routinely. Murphy staging was used. The first dose of chemotherapy (COP1) consisted of 300 mg cyclophosphamide (CPM), 1 mg vincristine, and 60 mg prednisone given on day 1 and followed by COP2 on day 8 (only for patients with larger tumour volumes, stage III or IV disease). The vincristine dose in COP2 was 2 mg. COMP1 and 2 given on days 22 and 36 consisted of 500 mg CPM, 2 mg vincristine, 60 mg prednisone, and 2 g methotrexate. All doses were calculated per body surface area. Intrathecal methotrexate and hydrocortisone were given with COP1 and 2. RESULTS: Forty-two patients, 30 boys and 12 girls median ages 6 and 7.5 years, respectively, had Murphy stage I(n5), II(n8), III(n21), and IV(n8) disease. The face was involved in 74%, abdomen in 55%, bone marrow in 14%, kidneys in 24%, and 12% had paraplegia. Fourteen children died during or shortly after completion of chemotherapy. Three of these were disease related. Twelve patients suffered a local relapse after 57-328 days, and one a CNS relapse at 76 days. The projected EFS at 12 months is 50% in stage I, 50% in stage II, 24% in stage III, 25% in stage IV, and 33% for all patients. The cumulative mean dose of CPM was 62 mg/kg in survivors and 64 mg/kg in children who relapsed. One third of patients experienced significant marrow suppression, and infections after COMP1. CONCLUSIONS: Thirty-three percent of children are in first remission at 12 months. The morbidity and mortality of treatment was high. The high relapse rate in all stages may be due to the low cumulative dose of CPM. (c) 2004 Wiley-Liss, Inc.
Authors: Katherine D Westmoreland; Nathan D Montgomery; Christopher C Stanley; Nader Kim El-Mallawany; Peter Wasswa; Toon van der Gronde; Idah Mtete; Mercy Butia; Salama Itimu; Mary Chasela; Mary Mtunda; Coxcilly Kampani; N George Liomba; Tamiwe Tomoka; Bal M Dhungel; Marcia K Sanders; Robert Krysiak; Peter Kazembe; Dirk P Dittmer; Yuri Fedoriw; Satish Gopal Journal: Int J Cancer Date: 2017-03-24 Impact factor: 7.396
Authors: Raul C Ribeiro; Eva Steliarova-Foucher; Ian Magrath; Jean Lemerle; Tim Eden; Caty Forget; Isabel Mortara; Isabelle Tabah-Fisch; Jose Julio Divino; Thomas Miklavec; Scott C Howard; Franco Cavalli Journal: Lancet Oncol Date: 2008-08 Impact factor: 41.316
Authors: Chin-Nam Bong; Solomon Cc Chen; Alexander David Barr; Kwongleung Yu; Tsung-Che Hsieh; Teck-Siong Tok; John A Phillips Journal: Malawi Med J Date: 2007-03 Impact factor: 0.875
Authors: George Chagaluka; Peter Carey; Kondwani Banda; Claire Schwab; Lucy Chilton; Ed Schwalbe; Roderick Skinner; Trijn Israels; Anthony Moorman; Elizabeth Molyneux; Simon Bailey Journal: Haematologica Date: 2012-08-16 Impact factor: 9.941
Authors: Christopher C Stanley; Kate D Westmoreland; Brett J Heimlich; Nader K El-Mallawany; Peter Wasswa; Idah Mtete; Mercy Butia; Salama Itimu; Mary Chasela; Mary Mtunda; Mary Chikasema; Victor Makwakwa; Bongani Kaimila; Edwards Kasonkanji; Fred Chimzimu; Coxcilly Kampani; Bal M Dhungel; Robert Krysiak; Nathan D Montgomery; Yuri Fedoriw; Nora E Rosenberg; N George Liomba; Satish Gopal Journal: Br J Haematol Date: 2016-02-23 Impact factor: 6.998
Authors: Matthew Ulrickson; Fred Okuku; Victoria Walusansa; Oliver Press; Sam Kalungi; David Wu; Fred Kambugu; Corey Casper; Jackson Orem Journal: J Natl Compr Canc Netw Date: 2013-03-01 Impact factor: 11.908
Authors: Geoffrey Buckle; Louise Maranda; Jodi Skiles; John Michael Ong'echa; Joslyn Foley; Mara Epstein; Terry A Vik; Andrew Schroeder; Jennifer Lemberger; Alan Rosmarin; Scot C Remick; Jeffrey A Bailey; John Vulule; Juliana A Otieno; Ann M Moormann Journal: Int J Cancer Date: 2016-05-18 Impact factor: 7.396